Related references
Note: Only part of the references are listed.Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease
Ronan Thibaut et al.
FEBS JOURNAL (2022)
Liver fibrosis: Pathophysiology and clinical implications
Jennifer Berumen et al.
WIRES MECHANISMS OF DISEASE (2021)
Promoted inhibition of TLR4/miR-155/ NFkB p65 signaling by cannabinoid receptor 2 agonist (AM1241), aborts inflammation and progress of hepatic fibrosis induced by thioacetamide
Alaa M. Ali et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2021)
Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease
Kasper W. ter Horst et al.
DIABETES CARE (2021)
Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials
Carine Beysen et al.
DIABETES OBESITY & METABOLISM (2021)
High-fructose feeding does not induce steatosis or non-alcoholic fatty liver disease in pigs
Nikolaj H. Schmidt et al.
SCIENTIFIC REPORTS (2021)
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Rohit Loomba et al.
CELL (2021)
Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis-Roles as Putative Treatment Targets?
Alexandra Zisser et al.
BIOMEDICINES (2021)
Roles of Endocannabinoids and Endocannabinoid-Like Molecules in Energy Homeostasis and Metabolic Regulation: A Nutritional Perspective
S. M. Khaledur Rahman et al.
ANNUAL REVIEW OF NUTRITION, VOL 41, 2021 (2021)
Hepatic stellate cells role in the course of metabolic disorders development - A molecular overview
Nabila Bourebaba et al.
PHARMACOLOGICAL RESEARCH (2021)
Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past
Oyekoya T. Ayonrinde
JHEP REPORTS (2021)
Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE*3-Leiden.CETP mice
Robin van Eenige et al.
JOURNAL OF LIPID RESEARCH (2021)
Peripherally Selective CB1 Receptor Antagonist Improves Symptoms of Metabolic Syndrome in Mice
Nayaab Khan et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)
Hepatic Stellate Cell Regulation of Liver Regeneration and Repair
Laura J. Kitto et al.
HEPATOLOGY COMMUNICATIONS (2021)
Cannabinoid receptor 1 knockout alleviates hepatic steatosis by downregulating perilipin 2
Karuna Irungbam et al.
LABORATORY INVESTIGATION (2020)
Hypoxia training improves hepatic steatosis partly by downregulation of CB1 receptor in obese mice
Qin Yang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
The peripheral CB1 receptor antagonist JD5037 attenuates liver fibrosis via a CB1 receptor/β-arrestin1/Akt pathway
Siwei Tan et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Novel Rho associated coiled kinase 2 (ROCK2) inhibitor reduces steatosis and fibrosis in mice model of liver disease
Quaisar Ali et al.
FASEB JOURNAL (2020)
Role of Cannabis and Its Derivatives in Gastrointestinal and Hepatic Disease
Jonathan Gotfried et al.
GASTROENTEROLOGY (2020)
Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease
Angeliki Katsarou et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2020)
Mitochondrial dysfunction in metabolic syndrome
Pankaj Prasun
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2020)
Novel Rho associated coiled kinase inhibitor improves hepatic fibrosis in mice model of non-alcoholic steatohepatitis (NASH)
Quaisar Ali et al.
JOURNAL OF HEPATOLOGY (2020)
Exacerbated LPS/GalN-Induced Liver Injury in the Stress-Sensitive Wistar Kyoto Rat Is Associated with Changes in the Endocannabinoid System
Marykate Killilea et al.
MOLECULES (2020)
Cannabis Extracts Affected Metabolic Syndrome Parameters in Mice Fed High-Fat/Cholesterol Diet
Tal Assa-Glazer et al.
CANNABIS AND CANNABINOID RESEARCH (2020)
The effect of cannabinoid receptor 1 blockade on adipokine and proinflammatory cytokine concentration in adipose and hepatic tissue in mice with nonalcoholic fatty liver disease
Bojan Jorgacevic et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2019)
Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats
Sabine Klein et al.
SCIENTIFIC REPORTS (2019)
Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis
Ivonne Bazwinsky-Wutschke et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Zobair M. Younossi et al.
JOURNAL OF HEPATOLOGY (2019)
Determining contributions of exogenous glucose and fructose to de novo fatty acid and glycerol synthesis in liver and adipose tissue
Joao C. P. Silva et al.
METABOLIC ENGINEERING (2019)
Dose-dependent quantitative effects of acute fructose administration on hepatic de novo lipogenesis in healthy humans
Carine Beysen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2018)
Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases
Varman T. Samuel et al.
CELL METABOLISM (2018)
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease
Mario Masarone et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2018)
CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes
Eugene Chang et al.
PLOS ONE (2018)
Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition
Hu Huang et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
The epidemiology of non-alcoholic fatty liver disease
Stefano Bellentani
LIVER INTERNATIONAL (2017)
Protective effect of rimonabant, a canabinoid receptor 1 antagonist, on nonalcoholic fatty liver disease in a rat model through modulation of the hepatic expression of activin A and follistatin
Noha I. Hussien et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2017)
The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease
Bojan Jorgacevic et al.
CHEMISTRY AND PHYSICS OF LIPIDS (2017)
Role of the endocannabinoid system in diabetes and diabetic complications
G. Gruden et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World
Mehmet Sayiner et al.
CLINICS IN LIVER DISEASE (2016)
Early Low-Fat Diet Enriched With Linolenic Acid Reduces Liver Endocannabinoid Tone and Improves Late Glycemic Control After a High-Fat Diet Challenge in Mice
Laurent Demizieux et al.
DIABETES (2016)
Pretreatment with Rho-kinase inhibitor ameliorates lethal endotoxemia-induced liver injury by improving mitochondrial function
Renyu Ding et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2016)
Unraveling the actions of AMP-activated protein kinase in metabolic diseases: Systemic to molecular insights
Karen A. Weikel et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Elena Buzzetti et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
Robert J. Wong et al.
GASTROENTEROLOGY (2015)
How Inflammation Impinges on NAFLD: A Role for Kupffer Cells
Nadia Duarte et al.
BIOMED RESEARCH INTERNATIONAL (2015)
De novo lipogenesis in metabolic homeostasis: More friend than foe?
Giovanni Solinas et al.
MOLECULAR METABOLISM (2015)
Rho-Kinase Inhibitor Targeting the Liver Prevents Ischemia/Reperfusion Injury in the Steatotic Liver Without Major Systemic Adversity in Rats
Shintaro Kuroda et al.
LIVER TRANSPLANTATION (2015)
Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease
Jennifer E. Lambert et al.
GASTROENTEROLOGY (2014)
Hepatic Cannabinoid-1 Receptors Mediate Diet-Induced Insulin Resistance by Increasing De Novo Synthesis of Long-Chain Ceramides
Resat Cinar et al.
HEPATOLOGY (2014)
Nonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes
Andreas L. Birkenfeld et al.
HEPATOLOGY (2014)
Liver X receptors in lipid metabolism: opportunities for drug discovery
Cynthia Hong et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Rho-Kinase Inhibition Ameliorates Metabolic Disorders through Activation of AMPK Pathway in Mice
Kazuki Noda et al.
PLOS ONE (2014)
Endocannabinoid Receptors Gene Expression in Morbidly Obese Women with Nonalcoholic Fatty Liver Disease
Teresa Auguet et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Reciprocal Regulation of Hepatic and Adipose Lipogenesis by Liver X Receptors in Obesity and Insulin Resistance
Simon W. Beaven et al.
CELL METABOLISM (2013)
The Endocannabinoid System in Energy Homeostasis and the Etiopathology of Metabolic Disorders
Cristoforo Silvestri et al.
CELL METABOLISM (2013)
ROCK1 in AgRP Neurons Regulates Energy Expenditure and Locomotor Activity in Male Mice
Hu Huang et al.
ENDOCRINOLOGY (2013)
The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives
Maurizio Baldassarre et al.
LIVER INTERNATIONAL (2013)
De novo lipogenesis in human fat and liver is linked to ChREBP-β and metabolic health
Leah Eissing et al.
NATURE COMMUNICATIONS (2013)
Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance
Joseph Tam et al.
CELL METABOLISM (2012)
Skeletal Muscle Insulin Resistance Promotes Increased Hepatic De Novo Lipogenesis, Hyperlipidemia, and Hepatic Steatosis in the Elderly
Clare Flannery et al.
DIABETES (2012)
HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects
Sabine Klein et al.
JOURNAL OF HEPATOLOGY (2012)
Rho inhibitor prevents ischemia-reperfusion injury in rat steatotic liver
Shintaro Kuroda et al.
JOURNAL OF HEPATOLOGY (2012)
Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Tatiana Kisseleva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings
A. Mallat et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant Mice
Yu Li et al.
CELL METABOLISM (2011)
Kupffer cell depletion prevents but has no therapeutic effect on metabolic and inflammatory changes induced by a high-fat diet
Nicolas Lanthier et al.
FASEB JOURNAL (2011)
Reduction of Fibrogenesis by Selective Delivery of a Rho Kinase Inhibitor to Hepatic Stellate Cells in Mice
M. M. van Beuge et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment
Briohny W. Smith et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Increased Liver Uptake and Reduced Hepatic Stellate Cell Activation with a Cell-Specific Conjugate of the Rho-kinase Inhibitor Y27632
Marike Marjolijn van Beuge et al.
PHARMACEUTICAL RESEARCH (2011)
Peripheral effects of the endocannabinoid system in energy homeostasis: Adipose tissue, liver and skeletal muscle
Cristoforo Silvestri et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2011)
Rho-Kinase Inhibitor Attenuates Cholestasis-Induced CXC Chemokine Formation, Leukocyte Recruitment, and Hepatocellular Damage in the Liver
Matthias W. Laschke et al.
JOURNAL OF SURGICAL RESEARCH (2010)
Critical role of Kupffer cells in the management of diet-induced diabetes and obesity
Audrey M. Neyrinck et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Hepatic stellate cell lipid droplets: A specialized lipid droplet for retinoid storage
William S. Blaner et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2009)
Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle
K. Eckardt et al.
DIABETOLOGIA (2009)
Presence of functional cannabinoid receptors in human endocrine pancreas
F. J. Bermudez-Silva et al.
DIABETOLOGIA (2008)
Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control
Vasantha Kolavennu et al.
DIABETES (2008)
Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis
Kumi Kitamura et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2007)
Rho-kinase inhibitor prevents hepatocyte damage in acute liver injury induced by carbon tetrachloride in rats
Hitoshi Ikeda et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2007)
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats
Magali Gary-Bobo et al.
HEPATOLOGY (2007)
Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury
Sandor Batkai et al.
FASEB JOURNAL (2007)
Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease
N. Mendez-Sanchez et al.
LIVER INTERNATIONAL (2007)
Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model
T. Ogawa et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Altered penile vascular reactivity and erection in the Zucker obese-diabetic rat
Christopher Wingard et al.
JOURNAL OF SEXUAL MEDICINE (2007)
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis
Fatima Teixeira-Clerc et al.
NATURE MEDICINE (2006)
Protective effect of fasudil, a Rho-kinase inhibitor, on chemokine expression, leukocyte recruitment, and hepatocellular apoptosis in septic liver injury
Karin Thorlacius et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
Comparative aspects of lipid metabolism: Impact on contemporary research and use of animal models
WG Bergen et al.
JOURNAL OF NUTRITION (2005)
Rho-kinase as a molecular target for insulin resistance and hypertension
T Kanda et al.
FASEB JOURNAL (2005)
Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges
E Hu et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Insulin acutely decreases hepatic fatty acid synthase activity
SM Najjar et al.
CELL METABOLISM (2005)
AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism
BB Kahn et al.
CELL METABOLISM (2005)
Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue
BA Laffitte et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Transcriptional regulation of hepatic stellate cell activation
DA Mann et al.
GUT (2002)
Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
Y Minokoshi et al.
NATURE (2002)
Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells
T Murata et al.
JOURNAL OF HEPATOLOGY (2001)
A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats
S Tada et al.
JOURNAL OF HEPATOLOGY (2001)
Share Paper
